![Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group - ScienceDirect Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1533002822X00042-cov150h.gif)
Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group - ScienceDirect
![Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group - ScienceDirect Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1533002822000408-gr1.jpg)
Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group - ScienceDirect
![Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group | British Journal of Cancer Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group | British Journal of Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41416-021-01474-y/MediaObjects/41416_2021_1474_Fig2_HTML.png)
Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group | British Journal of Cancer
![Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group | British Journal of Cancer Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-021-01474-y/MediaObjects/41416_2021_1474_Fig1_HTML.png)
Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group | British Journal of Cancer
![Tachyon Presents New Data Supporting the Development of TACH101, a Novel KDM4 Inhibitor, as a Potential Therapy for Gastrointestinal Cancers at the 2022 ASCO-GI Conference | Business Wire Tachyon Presents New Data Supporting the Development of TACH101, a Novel KDM4 Inhibitor, as a Potential Therapy for Gastrointestinal Cancers at the 2022 ASCO-GI Conference | Business Wire](https://mms.businesswire.com/media/20220120005171/en/1333313/23/TachyonLogo-FullColor-RGB.jpg)
Tachyon Presents New Data Supporting the Development of TACH101, a Novel KDM4 Inhibitor, as a Potential Therapy for Gastrointestinal Cancers at the 2022 ASCO-GI Conference | Business Wire
![Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group | British Journal of Cancer Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-021-01474-y/MediaObjects/41416_2021_1474_Fig1_HTML.png)